" class="no-js "lang="en-US"> Matt Segall - Medtech Alert
Wednesday, July 30, 2025
Matthew Segall

Matt Segall

About Matt Segall

Matt has a Master of Science in computation from the University of Oxford and a PhD in theoretical physics from the University of Cambridge. As Associate Director at Camitro (UK), ArQule Inc. and then Inpharmatica, he led a team developing predictive ADME models and state-of-the-art intuitive decision-support and visualization tools for drug discovery. In January 2006, he became responsible for management of Inpharmatica’s ADME business, including experimental ADME services and the StarDrop software platform. Following acquisition of Inpharmatica, Matt became Senior Director responsible for BioFocus DPI’s ADMET division and in 2009 led a management buyout of the StarDrop business to found Optibrium.

Related Story

Optibrium Strengthens Global AI Drug Discovery Software Operations With Three Key Appointments

October 4 2022

Optibrium, a leading developer of software and artificial intelligence (AI) solutions for drug discovery, today […]

Optibrium Receives Further Investment From Kester Capital

June 22 2022

Optibrium™, a developer of software for drug discovery, today announced it has secured further investment […]

Optibrium Expands UK Head Office With New Facilities on Cambridge Innovation Park

June 9 2022

Optibrium™, a developer of software for drug discovery, today announced the expansion of its UK […]